Evaluation of the anti-hepatitis C virus effects of cyclophilin inhibitors, cyclosporin A, and NIM811

Kaku Goto, Koichi Watashi, Takayuki Murata, Takayuki Hishiki, Makoto Hijikata, Kunitada Shimotohno

Research output: Contribution to journalArticle

115 Citations (Scopus)

Abstract

Hepatitis C virus (HCV) is a major causative agent of hepatocellular carcinoma. We recently discovered that the immunosuppressant cyclosporin A (CsA) and its analogue lacking immunosuppressive function, NIM811, strongly suppress the replication of HCV in cell culture. Inhibition of a cellular replication cofactor, cyclophilin (CyP) B, is critical for its anti-HCV effects. Here, we explored the potential use of CyP inhibitors for HCV treatment by analyzing the HCV replicon system. Treatment with CsA and NIM811 for 7 days reduced HCV RNA levels by 2-3 logs, and treatment for 3 weeks reduced HCV RNA to undetectable levels. NIM811 exerted higher anti-HCV activity than CsA at lower concentrations. Both CyP inhibitors rapidly reduced HCV RNA levels even further in combination with IFNα without modifying the IFNα signal transduction pathway. In conclusion, CyP inhibitors may provide a novel strategy for anti-HCV treatment.

Original languageEnglish
Pages (from-to)879-884
Number of pages6
JournalBiochemical and Biophysical Research Communications
Volume343
Issue number3
DOIs
Publication statusPublished - 12-05-2006
Externally publishedYes

Fingerprint

Cyclophilins
Viruses
Hepacivirus
Cyclosporine
RNA
Immunosuppressive Agents
(melle-4)cyclosporin
Signal transduction
Replicon
Cell culture
Hepatocellular Carcinoma
Signal Transduction
Cell Culture Techniques

All Science Journal Classification (ASJC) codes

  • Biophysics
  • Biochemistry
  • Molecular Biology
  • Cell Biology

Cite this

Goto, Kaku ; Watashi, Koichi ; Murata, Takayuki ; Hishiki, Takayuki ; Hijikata, Makoto ; Shimotohno, Kunitada. / Evaluation of the anti-hepatitis C virus effects of cyclophilin inhibitors, cyclosporin A, and NIM811. In: Biochemical and Biophysical Research Communications. 2006 ; Vol. 343, No. 3. pp. 879-884.
@article{d135032e0d7d4d8ea2636ca1814a9f67,
title = "Evaluation of the anti-hepatitis C virus effects of cyclophilin inhibitors, cyclosporin A, and NIM811",
abstract = "Hepatitis C virus (HCV) is a major causative agent of hepatocellular carcinoma. We recently discovered that the immunosuppressant cyclosporin A (CsA) and its analogue lacking immunosuppressive function, NIM811, strongly suppress the replication of HCV in cell culture. Inhibition of a cellular replication cofactor, cyclophilin (CyP) B, is critical for its anti-HCV effects. Here, we explored the potential use of CyP inhibitors for HCV treatment by analyzing the HCV replicon system. Treatment with CsA and NIM811 for 7 days reduced HCV RNA levels by 2-3 logs, and treatment for 3 weeks reduced HCV RNA to undetectable levels. NIM811 exerted higher anti-HCV activity than CsA at lower concentrations. Both CyP inhibitors rapidly reduced HCV RNA levels even further in combination with IFNα without modifying the IFNα signal transduction pathway. In conclusion, CyP inhibitors may provide a novel strategy for anti-HCV treatment.",
author = "Kaku Goto and Koichi Watashi and Takayuki Murata and Takayuki Hishiki and Makoto Hijikata and Kunitada Shimotohno",
year = "2006",
month = "5",
day = "12",
doi = "10.1016/j.bbrc.2006.03.059",
language = "English",
volume = "343",
pages = "879--884",
journal = "Biochemical and Biophysical Research Communications",
issn = "0006-291X",
publisher = "Academic Press Inc.",
number = "3",

}

Evaluation of the anti-hepatitis C virus effects of cyclophilin inhibitors, cyclosporin A, and NIM811. / Goto, Kaku; Watashi, Koichi; Murata, Takayuki; Hishiki, Takayuki; Hijikata, Makoto; Shimotohno, Kunitada.

In: Biochemical and Biophysical Research Communications, Vol. 343, No. 3, 12.05.2006, p. 879-884.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Evaluation of the anti-hepatitis C virus effects of cyclophilin inhibitors, cyclosporin A, and NIM811

AU - Goto, Kaku

AU - Watashi, Koichi

AU - Murata, Takayuki

AU - Hishiki, Takayuki

AU - Hijikata, Makoto

AU - Shimotohno, Kunitada

PY - 2006/5/12

Y1 - 2006/5/12

N2 - Hepatitis C virus (HCV) is a major causative agent of hepatocellular carcinoma. We recently discovered that the immunosuppressant cyclosporin A (CsA) and its analogue lacking immunosuppressive function, NIM811, strongly suppress the replication of HCV in cell culture. Inhibition of a cellular replication cofactor, cyclophilin (CyP) B, is critical for its anti-HCV effects. Here, we explored the potential use of CyP inhibitors for HCV treatment by analyzing the HCV replicon system. Treatment with CsA and NIM811 for 7 days reduced HCV RNA levels by 2-3 logs, and treatment for 3 weeks reduced HCV RNA to undetectable levels. NIM811 exerted higher anti-HCV activity than CsA at lower concentrations. Both CyP inhibitors rapidly reduced HCV RNA levels even further in combination with IFNα without modifying the IFNα signal transduction pathway. In conclusion, CyP inhibitors may provide a novel strategy for anti-HCV treatment.

AB - Hepatitis C virus (HCV) is a major causative agent of hepatocellular carcinoma. We recently discovered that the immunosuppressant cyclosporin A (CsA) and its analogue lacking immunosuppressive function, NIM811, strongly suppress the replication of HCV in cell culture. Inhibition of a cellular replication cofactor, cyclophilin (CyP) B, is critical for its anti-HCV effects. Here, we explored the potential use of CyP inhibitors for HCV treatment by analyzing the HCV replicon system. Treatment with CsA and NIM811 for 7 days reduced HCV RNA levels by 2-3 logs, and treatment for 3 weeks reduced HCV RNA to undetectable levels. NIM811 exerted higher anti-HCV activity than CsA at lower concentrations. Both CyP inhibitors rapidly reduced HCV RNA levels even further in combination with IFNα without modifying the IFNα signal transduction pathway. In conclusion, CyP inhibitors may provide a novel strategy for anti-HCV treatment.

UR - http://www.scopus.com/inward/record.url?scp=33645911783&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645911783&partnerID=8YFLogxK

U2 - 10.1016/j.bbrc.2006.03.059

DO - 10.1016/j.bbrc.2006.03.059

M3 - Article

VL - 343

SP - 879

EP - 884

JO - Biochemical and Biophysical Research Communications

JF - Biochemical and Biophysical Research Communications

SN - 0006-291X

IS - 3

ER -